Company: SVREW
Filing Date: 2025-04-03
Form Type: 424B3
Source: 0001213900-25-028398
Chunk: 21

Company: SaverOne 2014 Ltd.
Filing Date: 2025-04-03
Form: 424B3
Chunk 21
---
. Accordingly, if the bid price of our ADS again fails below $1 for another consecutive 30 day trading period, prior to October 2026, our ADS will be subject to immediate delisting from Nasdaq. In addition, we may in the future fail to meet other continued Nasdaq listing requirements, and if we are not eligible to receive any compliance period from Nasdaq, our ADS will be immediately delisted to over-the-counter market. If this were to occur, it would have a material adverse effect on our business. Our shareholders could face significant material adverse consequences, including limited availability of market quotations for ADSs and reduced liquidity for the trading of our securities. In addition, we could experience a decreased ability to issue additional securities and obtain additional financing in the future. There can be no assurance that an active trading market for ADSs will develop or be sustained. As a result of these factors, if our ADSs are delisted from Nasdaq, the price of the ADSs is most likely to decline. The delisting of our ADSs from Nasdaq could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities. If our ADSs are delisted from Nasdaq, we would remain a publicly traded company on the TASE and revert to being subject to full Israeli securities laws and disclosure requirements. Accordingly, we will need to comply with U.S. and Israeli disclosure requirements, and we expect that these additional reporting requirements would increase our legal and financial compliance costs and require significant management time.

Sales of a substantial amount of our Ordinary Shares or ADSs, including resale of the held by the Selling Shareholders in the public market could adversely affect the prevailing market price of our ADSs.

We are registering for resale under this prospectus up to 404,537,940 Ordinary Shares represented by 337,200 ADSs upon exercise of the Warrant in connection with the January 2025 Offering, from time to time, subject to the conditions set forth in the Purchase Agreement. If all Selling Shareholders exercise their Warrants and sell the ADSs pursuant to this prospectus, it will result in the sale of the substantial number of our Ordinary Shares or ADS in the public market. Such sales of a substantial number of our Ordinary Shares or ADSs in the public market, or the perception that such sales might occur, could adversely affect the market price of our Ordinary Shares, and the market value of our other securities. We cannot predict if and when the Selling Share